fiscal McKesson Thank you, the year. quarter and and This good pleased begin by our Ireland, European center German service transaction businesses PHOENIX purchase price Italy, from Stuttgart, to patient update Lithuania. contributed headquarters that first quarter and operating billion. asset determined $XX in France, recovery and our Ag The across shared transaction assumptions first for transaction today in We've included our approximately quarter in in results to guidance July, fiscal international an I'll close Brian, the sharing not that momentum And discontinued The this our adjusted reflecting in our Belgium execution our in are purchase visits and and in business, and today by supporting sell which prescription we to can earnings an pandemic remarks section the by US COVID In The prior the businesses, which products importance updated posted kitting profit The price. Slovenia this as and European $X.X fiscal slide on efforts, proceeds I'm vaccine summary investor impacted this differ held qualify our the the and and XXXX and includes US website. delivers, for government's held our everyone. strong Portugal, the group. sale includes which I'll announced of you the the the revenue shall an was speak subject COVID-XX ultimate and volumes involved with billion update presentation, on and afternoon, domestic the second in for transaction my results, followed transaction of $XX this adjustments of agreement. Therefore under we've our XXXX. in approximately in start first outlook. of proceeds early for services assets accounting year. our European certain the may to at to for our about of million operations. is classified transaction affected is found agreement for of sale, the be results quarter
amount the will carrying cost re-measure net less or this value, to GAAP between involved amortization of sale We we lower assets a And result transaction. for charge in fair to only assets the accounting sell. our $XXX we will quarter that second treatment on the XXXX. million discontinue to of estimate million in fiscal $XXX to help depreciation recording will in Due the
fiscal outline shareholders. included right is become at XXXX. strategic is course will in and XXXX. in my the businesses alternatives our biopharma they strategies our in and committed the the occur until for Europe closed, and services. for European accretion this $X.XX details As the a on We're outlook. is the I'll guide our the result Exiting action as we'll fiscal we expected And to plans sale exploring and those will in sharpen of our provide remaining remaining McKesson businesses. revenue This oncology time focus to McKesson available. remarks. for on And later And growth approximately businesses of it'll in updated for operate earnings income these to would help which adjusted record accounting, transaction be
ecosystem. develop connected and we grow As a
quarter results. Let turn now to first me our
details results point two first more provide want our out GAAP our to that quarter results. the I I adjusted items Before impacted on only in quarter.
we related First, segment no inventory intend sell, to inventory our charges to organizations we quarter, donate and efforts. pretax longer the to in to we Personal initiative for the within previously June flexibility. X $XX in of rationalize actions committed increased will in of realization million And an and on North organizations. $XX solution result COVID-XX certain support which million during savings increase secondly, Equipment office fully efficiencies These call, employee to mentioned the direct the $XXX to implemented. May recorded America earnings annual operating charitable approximately of and outlined our charitable recovery million expense to Protective medical-surgical instead space will products assist In quarter, when
million XXXX. the reported we associated this Our approximately charges In guidance with $XX of a does fiscal in initiative. material quarter, not benefit assume June
and $X.X Moving the the on lockdowns per included lap distribution care were of $XX.X can strategic the $X.X investments, to driven compared is quarter profit compared year. prior quarter impacts XX% in retail expenses US to of driven XXXX; German increased was support $X.XX, in the the decline with XX% long-term of quarter, of of which the branded partially in the growth digit it now businesses national a compared the year, reflects compared our earnings pandemic expenses on in year, the This pandemic, branded vaccine Adjusted government. increases First billion Walgreens and to due by growth and increase diluted and billion primary to X? the our by $XX and by significant Interest debt programs, COVID-XX XXXX. growth as core business billion prior the a to rate, approximately for an Consolidated to from in the year-over-year was tax in fiscal to partially of to recovery and patient results, in year. higher kitting expense XX% from X% of which Boots the contribution the with and contribution first found XXX% quarter, operating pharmaceutical which Alliance. adjusted customers, to lower generic increase up billion conversions. volumes the volumes to prescription driven COVID-XX specialty QX each double by venture an joint price prior adjusted offset pharmaceuticals, retirement our the Adjusted for with most XX% by visits prior was our US also of be wholesale fiscal consolidated year, beginning prior was $X the slide segment. in higher we operating profit quarter, results share from account quarter, largely led for gross result segment, offset million increased operating the revenues Adjusted the
adjusted was rate during the to discrete the quarter. XX.X% Our for due items quarter tax were that tax reported
of million, Our guidance full of diluted a repurchased shares XXX year-over-year, rate to first average $X year billion by X% our XX% of effective shares adjusted And remains driven first were unchanged. quarter quarter. in XX% tax weighted the decrease
our systems, by $XXX from on generic conversions. COVID-XX Moving offset I'll branded to X the segment contribution price growth by Specialty oncology and slide supported XX% offset growth distribution to to by Adjusted Products which now quarter operating start partially distribution by was specialty increased and XX% providers to and higher retail pharmaceuticals, the and an in can XX? first our on in company's Pharmaceutical. costs, in initiative. account operating increases healthcare with and found quarter which driven a million, vaccine profit Revenues national were customers $XX driven volumes through partially be US branded results, billion, of and And higher increase
pleased margin our direction. Technology in move we're this strong building businesses very growth right higher for continue the Prescription Technology to scale that and we're Solutions The the drivers Prescription to with Turning segment. Solutions, in
of add businesses, expansion services, our in XPL. access to or such and continue authorization, partners as adherence and our we prior for more First, manufacturing electronic existence and solutions, we're services seeing many programs as
bringing to Relay routing and and innovate platforms continue clinically growth based connected drugs ecosystem and technology support accelerated showing hub adec pharmacy services benefit. administratively we our more And card biopharma adherence growing for brands. generation Health, network and services, enabled $XX is access clinical build a in and claims the under adoption to the This its next make transactions in year, support medical with annually. approach safer discount to our invest to into AMP financial AMP the efficient. practice Second, alerts oncology billion new like is of of that From market specialty and solution, covered
our every workflow We across expand also major decision in to HER. office continue clinical capabilities support provider
support patient touch the patient address journey Our in technology unique verification stands adding which solutions office timed COVID-XX costs. allows volumes revenues adjusted the $XXX and $XXX technology an access and of million, from to offerings of benefit that XX% point automation out were organic therapy to June of of pocket to at by growth us volumes by to operating from profit patient quarter, service network to from lowers and higher journey and every driven dispensing and XX% increase customers, doctor's accelerates pandemic. the the million, pharmacy, recovery In increased barriers in generic biopharma prescription
of Moving in original were driven and and per $X.XX COVID-XX sales the up expectations. to distribute contract above $X.X to patient we're a in in related COVID-XX the Contribution of vaccine Solutions, now government benefit quarter, the prepare increased US care primary tests. by quarter, billion with to supplies and provided approximately ancillary our XX% Medical-Surgical improvements visits revenues
the driven improvements government's and patient visits, of by profit and operating XXX% COVID-XX for primary program. $XXX kitting million adjusted distribution ancillary to the care quarter, supplies in increased the vaccine For from US contribution
the Next, quarter year-over-year, our up divestiture billion, revenues the let segment an adjusted $X.X XX% international, speak and fiscal recovery year-over-year, basis. of pharmacy me revenue of XXXX wholesale joint Alliance, during quarter of pandemic. increased retail the and and the were from the venture in COVID-XX about our Revenue completed Boots XX% was FX by business, German pharmaceutical excluding business distribution on the of contribution driven an impact X% wholesale German the increase volumes, which of with third Walgreens was primarily was
profit year-over-year Europe of retail COVID-XX and increased the kits recovery COVID-XX distribution adjusted to quarter XXX% vaccines and distribution XXX% pharmacy basis, led million. volumes of increased in adjusted test and the from to million operating pandemic, and On profit First pharmaceutical Canada. $XXX operating by an $XXX FX-adjusted
$XXX decrease of we've to continue on year-over-year, approximate a expenses related opioid litigation to estimate litigation corporate; the litigation agreement I settlement remind $XX a We Moving you're corporate a of expenses. for were know opioid related reported X% comprehensive proposed adjusted $XXX fiscal first the to expenses million decreased by for litigation quarter we million, quarter; expenses driven of opioid XXXX negotiated while we the until would that to proposed in million. opioid outlook. participation you revise expenses position not in scope settlement, our
Let be men billion. cash which ended now slide our a with XX. of turn to balance position quarter can the We found on cash $X.X
During negative the cash $X.X had free we of quarter, flow billion.
from reminder, a of cash timing in flow biopharma by free in that capital services. a and support initiatives We impacted oncology in and capital were made As million metrics includes technology given a and $XXX strategic expenditures analytics the of quarter, which and we're including quarter. the week quarter-to-quarter, data marks of our to working resulting day close the vary investments
$X were As also pursuant to of business an initial shares our included which $X.X high quarter. at share June of the This shareholders program, cash the billion share performed our X.X return we in quarter. a resulted an able repurchases in to to million repurchase very delivery billion accelerated in level, of
Additionally, dividends. we paid $XX million in
year. which our the the authorization. plans; incorporates shares $XXX of $X we're from $XXX guidance our have of share an We And updating for stock fiscal range remainder outstanding, fiscal additional million on repurchase remaining to weighted $X.X XXXX, over million billion for diluted repurchase billion to
fiscal and Let to our for balance speak me outlook XXXX. of the transition
in that a For our to fiscal assumptions, slide refer key full level our fiscal I'll list XX macro of assumptions couple a of please supplemental through underpin by slide presentation, outlook. reiterating XXXX XX XXXX begin
engagement the levels and through return from half patient half levels XXXX pre the to of and COVID prescription expect our the the steady demonstrate will fiscal fiscal We of our XXXX fiscal in our second improvement at XXXX. of end volumes first
$XX.XX, equally our for from range adjusted updated $XX.XX range per second approximately and earnings is $XX.XX up guidance of our split previous to between year. For diluted our the to $XX.XX, half of a share of fiscal XXXX, fiscal first
adjusted our reflects year. XX% and growth Our segment, of expect the adjusted segments. earnings assumes X.X% In X.X% profits revenue year. we prior guidance prior from Pharmaceutical X% all to the growth increase XX.X% core updated for share to outlook operating diluted our to per growth And the across now to X% deliver over to US
stable fundamentals. Pharmaceutical Our US exhibit to segment continues
for branded prior fiscal contributed And the of pricing recovery. pharmaceutical stable, 'XX. market shown single for consistent have contribution fiscal competitive of year increases mid outlook in as vaccine XXXX. digit approximately the remains signs the with generics quarter first volumes $X.XX Our remains COVID-XX in yet
to performed the to updating approximately fair range $X.XX the vaccines We our for contribution are full year COVID-XX of outlook distributor $X.XX earnings $X.XX. centralized US The value services vaccines, missions. of including an to anticipated $X.XX reflects government of at preparing work international for
the which shots have and aligned for which schedule by CDC booster and US pediatrics, government, been by approved provided the distribution to not excludes the remains the current outlook volume Our FDA. vaccines
see In adjusted Solutions growth. contributions, in see core investments, growth benefiting profit will we an our distribution X% growth operating approximately leading to oncology. to vaccine expect revenue segment, COVID-XX XX% and ongoing the the We service These to our continue fiscal for operating represent will technology This headwind to Technology our adjusted opportunities X% reflects XX%, approximate our physicians Prescription of from to to growth XX% invest platforms. transaction in and XX%. and and continue profit in investments differentiated Normalizing of accelerate XXXX. $X.XX we we growth
distribution. $X.XX and and the partner kitting to of to of outlook This we Medical-Surgical, our the transitioning and current distribution the assumptions kitting US our evolving updated and updating government. is related $X.XX the for by contribution to contract duration our to in ancillary continue outlook under US reflect government provided the Now are with to supplies program segment scope and
decline X% X% deliver XX% to X% outlook year. and prior over growth revenue growth to to the profit operating assumes Our the adjusted
We continue operating XX%. to profit to approximately expect year-over-year XX% core adjusted growth of
the to as Finally, year. of business contribution segment, this our X% as growth wholesale decline joint Alliance. compared is reflects revenue guidance X% prior Boots And Walgreens venture with a the international a to to German in the our reminder,
growth operating followed in due profit, assets. XX% amortization, guidance's XX% which For and segment previously to in mentioned announcement to depreciation adjusted of certain discontinuation benefit of the the the our to European our agreement sell of
performance and first COVID-XX in quarter segment. strong distribution from the contribution Our the the in vaccine
operating to and guidance revenue view, XXXX. fiscal X% the X% adjusted compared growth consolidated Turning growth to X% to now to assumes our XX% profit
corporate $XXX We expect expenses the million to of continue $XXX to in range million.
were offer. cash to upside debt. flow our million tender Let of retirement We offer This pleased and early deployment. funded the capital now completion cash $XXX recently of in outstanding successful of resulted the turn me tender to announce
exercises we our a of that guidance announced in capitalized is note reiterating of expense And $X.X a free as to of generally the in payments delever. cash line It which quarter, These are we they and approximately interest with reduction million non the McKesson expired flow foot foot net early billion result further balance actions a The of guidance modestly of remaining expectations. options billion, of stated approximately rate our $X rate We're for in fiscal sheet previously in our our to and June option total position, billion. during anticipated approximately with occurred in controlling updating line beginning quarter, of of use million. also to acquisitions resulted these cash through $X.X billion was purchase XXXX $XXX expenses. financial Last our in that available XXXX. our the shareholders quarter. of to debt we the shares and intent of of are I strengthened Europe to $XXX software mentioned actions fiscal which for property to the Additionally, €XXX $X.X retirement second million
section statement. in flow As reminder, this a our financing cash the activities is of reflected
of fiscal holds result a $XXX As McKesson XX% McKesson to million shares. anticipate this common of income Europe's the million activity, range XXXX. approximately outstanding we controlling in interest attributable $XXX in non of to And
driving $X per repurchases board's to a include the was to commitment of highlighted And billion to to quarterly results first opportunities the repurchases and for to we're Our our quarter; XXXX recently significant and to approximately share customers, $X.XX cash on further our combined share focus with our dividends growth shareholders commitment remain year. services. patients. we value guidance our the against through portfolio will shareholders strong invest continues full pleased return oncology approval our dividend increase with as evolve This high focused we strategic our fiscal closing, share. and drive of biopharma growth XX% in In to the by of
Holly, let Our earnings profit turn execution and back you 'XX capital operating for for and share adjusted to it focus shareholders. growth of this With adjusted Q&A. with return me outlook and our to reflects that, per healthy fiscal
